Prevention of Bladder Cancer Recurrence With the Botanical Formula LCS103: A Case Series Study

Keyphrases

• Non-muscle Invasive Bladder Cancer (NMIBC) 100%
• Bladder Recurrence 100%
• Chemotherapy 50%
• Urological Symptoms 50%
• General Well-being 50%
• Adverse Events 50%
• Prospective Randomized Trial 50%
• Recurrence Rate 50%
• Bladder Cancer 50%
• Anticancer Activity 50%
• Tumor Recurrence 50%
• Metastatic Disease 50%
• Clinical Efficacy 50%
• Pain Frequency 50%
• Urination 50%
• Oncological Treatment 50%
• Cancer 2 50%
• Nocturia 50%
• Bladder Cancer Cells 50%
• Intravesical Treatment 50%
• Oncology Care 50%

Medicine and Dentistry

• Bladder Cancer 100%
• Cancer Recurrence 100%
• Oncology 66%
• Non Muscle Invasive Bladder Cancer 66%
• Recurrent Disease 33%
• Cancer Cell 33%
• Adverse Event 33%
• Weakness 33%
• Metastatic Carcinoma 33%
• Recurrence Risk 33%
• Tumor Recurrence 33%
• Antineoplastic Activity 33%
• Mycobacterium Bovis BCG 33%
• Nocturia 33%
• Pain (Symptom) 33%
• Intravesical Drug Administration 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Bladder Cancer 100%
• Cancer Recurrence 100%
• Non Muscle Invasive Bladder Cancer 66%
• Malignant Neoplasm 33%
• Chemotherapy 33%
• Recurrent Disease 33%
• Weakness 33%
• Adverse Event 33%
• Recurrence Risk 33%
• Tumor Recurrence 33%
• Mycobacterium Bovis BCG 33%
• Nocturia 33%